Salud financiera de hoja de balance de Botanix Pharmaceuticals

Salud financiera controles de criterios 5/6

Botanix Pharmaceuticals tiene un patrimonio de los accionistas total de A$108.7M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$112.5M y A$3.7M respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$79.31m
Patrimonio	AU$108.73m
Total pasivo	AU$3.73m
Activos totales	AU$112.46m

Actualizaciones recientes sobre salud financiera

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Jan 12

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$82.9M) de BOT superan a sus pasivos a corto plazo (A$3.7M).

Pasivo a largo plazo: BOT no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: BOT está libre de deudas.

Reducción de la deuda: BOT no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BOT tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si BOT tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Botanix Pharmaceuticals

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Recent updates

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

New minor risk - Share price stability

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

MD, President & Executive Chairman exercised options to buy AU$370k worth of stock.

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera